Skip to content

Developing oral oxytocin as an adjunct treatment for autism spectrum disorder: a randomized clinical trial

Developing oral oxytocin as an adjunct treatment for autism spectrum disorder: a randomized clinical trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090166
Enrollment
Unknown
Registered
2024-09-25
Start date
2024-09-25
Completion date
Unknown
Last updated
2025-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Interventions

Placebo:oromucosal administration of placebo freeze dried on the surface of a sugar-free lollipop every other day for 12 weeks followed after 30 min by a 30 min positive social interaction with an adu
Oxytocin low dose (12IU):oromucosal administration of 12IU oxytocin acetate freeze dried on the surface of a sugar-free lollipop every other day for 12 weeks followed after 30 min by a 30 min positive
Oxytocin medium dose (24IU):oromucosal administration of 24IU oxytocin acetate freeze dried on the surface of a sugar-free lollipop every other day for 12 weeks followed after 30 min by a 30 min posit
Oxytocin high dose (48IU):oromucosal administration of 48IU oxytocin acetate freeze dried on the surface of a sugar-free lollipop every other day for 12 weeks followed after 30 min by a 30 min positiv

Sponsors

University of Electronic Science and Technology of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 6 Years

Inclusion criteria

Inclusion criteria: Children (male or female) aged between 2 and 6 years diagnosed with autism spectrum disorder by DSM-V and scoring 5 or higher on the ADOS-2 comparison score.

Exclusion criteria

Exclusion criteria: Any children receiving psychotropic medications during the course of the trial or with any identified genetic or chromosomal abnormalities (Fragile X or Rett syndromes) or diagnosed with a neurological disease (e.g., epilepsy, cerebral palsy), or psychiatric disorder other than autism spectrum disorder or severe respiratory, hearing,or visual impairments.

Design outcomes

Primary

MeasureTime frame
Autism Diagnostic Observation Schedule - 2 (ADOS-2) score;Social Responsivity Scale-2 (SRS-2) score;

Secondary

MeasureTime frame
Griffiths Mental Development Scale-Chinese (GDS-C) score;Childhood Autism Rating Scale (CARS) score;Repetitive Behavior Scale-Revised (RBS-R) score;Adaptive Behavior Assessment Schedule – 2 (ABAS-2) score;Psychoeducational Profile 3rd edition (PEP-3) score;Caregiver strain questionnaire (CSQ) score;Brain structural magnetic resonance imaging;Brain resting state functional magnetic imaging;Genotype data;Oxytocin concentration in blood;Oxytocin concentration in saliva;Cytokine concentrations in blood;Eye tracking measures of social attention;

Countries

China

Contacts

Public ContactKeith Kendrick

University of Electronic Science and Technology of China

k.kendrick.uestc@gmail.com+86 158 2829 3346

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026